

A blue stethoscope is positioned diagonally across the frame, with its chest piece in the lower-left and its tubing curving towards the upper-right. The background is a soft, light blue gradient with some bokeh light effects.

Health Officer Report

Tracie Newman, MD, MPH, FAAP

Fargo Cass Public Health

6/23/22

COVID-19 Vaccine

FDA granted EUA for:


- Pfizer's 3-dose vaccine for ages 6 months – 4 years
- Moderna's 2-dose vaccine for ages 6 months – 6 years

Both recommended by CDC and AAP

For now, FCPH (and Sanford and Essentia) receiving Pfizer vaccine for < 5 age group


COVID-19 Vaccine < 5 dosing

- Pfizer
 - 3 weeks between dose 1 & 2
 - 8 weeks between dose 2 & 3
 - Entire series can be given within 3 months
- Moderna
 - 4 weeks between dose 1 & 2
 - Entire series can be given within 1 month
 - Trials underway testing a 3rd dose
 - Trials testing vaccine for ages 3 -6 months



COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

Number and intervals of COVID-19 vaccine doses



* Age-appropriate mRNA COVID-19 vaccines are preferred over Janssen COVID-19 Vaccine for primary and booster vaccination. Janssen COVID-19 Vaccine should only be used in limited situations. See: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#considerations-Janssen>.

For more specific clinical guidance, see:

- [Interim COVID-19 Immunization Schedule](#)
- [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)



Pfizer Vaccine

Trial enrolled 4500 children

- 1678 children < 5 years received 3 doses

Strong immune response:
80.3% effective in preventing
symptomatic infection

- Immune response (1 month after 3rd dose) compared favorably to that of 2 doses in ages 16 – 25

No new safety issues signaled

Majority of side effects mild –
moderate

Trial mostly conducted prior
to Omicron

* No cases of myocarditis or
pericarditis

Moderna Vaccine

Trial enrolled 11,700
ages 6 months – 12
years

- 6700 < age 6 years

All received 2 doses
given 4 weeks apart

51% effective against
symptomatic
infection in ages 6
months – 2 years

37% effective against
symptomatic
infection in ages 2 – 5
years

For both age groups,
favorable immune
responses compared
to adults ages 18 – 25

No new safety
concerns

Side effects mild –
moderate, mostly
after 2nd dose

Trial conducted
during Omicron wave

Higher vaccine efficacy in
adults (95%) – those vaccines
created to match original
virus. The vaccine continues to
be very helpful in reducing
disease severity and death

* No cases of
myocarditis or
pericarditis

* Moderna testing
Omicron-specific
booster

Where are we with COVID-19 vaccine uptake?




Nationally, only 29% of kids ages 5 – 11 are fully vaccinated

60% of US kids ages 12 – 17 are fully vaccinated

There are around 18 million kids < 5 years in the US

As of Feb 2022, 3/4 of children have had COVID-19 infection, according to CDC data



Everyone 6 months and older now can receive a safe and effective COVID-19 vaccine. The vaccine will continue to be the most effective tool to fight this virus. As more variants of COVID-19 are inevitable, it is important for families to take this opportunity to protect their kids.

MONKEYPOX UPDATE

As of June 21, **3,098** confirmed or probable monkeypox cases have been identified in **41** countries, including **141** in the US.

Global Cases
3,098

US Cases
141



www.cdc.gov/poxvirus/monkeypox/response/2022/world-map



CS332385-B 06/22/2022



Resources

CDC

[Vaccines and Related Biological Products Advisory Committee June 14-15, 2022 Meeting Briefing Document- FDA- Pfizer- COVID19 Vaccine for Pediatrics](#)

[Vaccines and Related Biological Products Advisory Committee June 14-15, 2022 Meeting Briefing Document- FDA- COVID19 Moderna Vaccine For Use in Pediatrics](#)

[Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose | Pfizer](#)

[Moderna-Announces-its-COVID-19-Vaccine-Phase-23-Study-in-Children-6-Months-to-Under-6-Years-Has-Successfully-Met-Its-Primary-Endpoint-2022.pdf \(q4cdn.com\)](#)

[Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 | MMWR \(cdc.gov\)](#)